CN Bio Innovations Ltd (CN Bio), an expert in developing human biomimetic platforms to test and develop therapeutics for serious diseases, announced today the opening of a new facility, including state-of-the-art Biosafety level 3 (BSL-3) laboratories, in Welwyn Garden City, UK. The BSL-3 laboratories will be dedicated to research, development and drug discovery alliance programmes based on the company’s proprietary in vitro models of viral liver infection, including Hepatitis B. The new facility will additionally comprise BSL-2 laboratories, an engineering laboratory and office space.
- De-risking drug-induced liver injury through the predictive power of organ-on-a-chip 7th December 2021
- PhysioMimix™ Multi-Organ Microphysiological System selected by The Scientist as a ‘Top 10 Innovation 2021′ 1st December 2021
- CN Bio and iiCON announce COVID-19 research collaboration 9th November 2021